Hydroxyurea reduces pain in young sickle-cell disease patients

BABY-HUG trial results indicate that hydroxyurea significantly reduces pain events in children with sickle-cell disease, and was also associated with reduced gastroenteritis, acute chest syndrome, transfusions and hospitalizations.